---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-002572"
form_type: "8-K"
ticker: "PROF"
cik: "0001628808"
company_name: "Profound Medical Corp."
filed_at: "2025-04-29T23:59:59+00:00"
generated_at: "2026-05-23T03:51:01.219837+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# CAPTAIN trial: TULSA shows zero blood loss, shorter stay vs robotic prostatectomy (p<0.001)

## Summary
- Median blood loss 0 mL (TULSA) vs 100 mL (RP); length of stay 0.29 vs 1.24 days (p<0.001).
- Significantly lower post-operative pain (NRS) through day 6 and higher overall health (EQ-5D-5L VAS) for 30 days (p<0.05).
- Fewer TULSA patients reported extreme problems in mobility (0% vs 12%), self-care (3% vs 17%), usual activities (17% vs 40%) in first month.
- First Level 1 RCT comparing TULSA to radical prostatectomy; 201 patients randomized across 23 sites.
- CEO notes data supports insurance coverage decisions; company expects further follow-up reporting.

## SEC filing metadata
- accession: 0001171843-25-002572
- form_type: 8-K
- ticker: PROF
- cik: 0001628808
- company_name: Profound Medical Corp.
- filed_at: 2025-04-29T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1628808/000117184325002572/0001171843-25-002572-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1628808/000117184325002572/f8k_042825.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-002572
- JSON: https://secwatch.observer/filing/0001171843-25-002572.json
- Plain text: https://secwatch.observer/filing/0001171843-25-002572.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.